Sandy Srinivas

Medical oncologist, Urologic specialist, Genitourinary specialist

Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

Urologic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Residency: St Mary's Hospital - New York (1991) NY

Internship: St Mary's Hospital - New York (1991) NY

Board Certification: Medical Oncology, American Board of Internal Medicine (1997)

Medical Education: Madras University Medicine (1985) India

Fellowship: UCSF Medical Center (1994) CA

Honors & Awards

Oncology Clinical Fellows Teaching award, Stanford University (2009)

Oncology Clinical Fellows Teaching award, Stanford University (2008)

Oncology Clinical Fellows teaching award, Stanford University (2007)

Oncology Clinical Fellows Teaching award, Stanford University (2006)

Oncology Clinical Fellows Teaching award, Stanford University (2005)

Oncology Clinical Fellows teaching award, Stanford University (2004)

Oncology clinical fellows teaching award, Stanford University (2003)

Medicine Chief residents teaching award, Stanford University (2003)

Oncology Teaching award, Stanford University (2002)

Administrative Appointments

Unit based Medical Director, Stanford Hospital (2012 - Present)

Prostate Panel member, NCCN (2002 - Present)

DSMC Vice Chair, Stanford University (2002 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed, N., Lee, J.-L., Srinivas, S., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2014). A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. Clinical genitourinary cancer, 12(4), e127-31.

Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy
Kroeger, N., Choueiri, T. K., Lee, J.-L., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2014). Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. EUROPEAN UROLOGY, 65(6), 1086-1092.

Prostate cancer, version 2.2014.
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2014). Prostate cancer, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(5), 686-718.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
Ko, J. J., Choueiri, T. K., Rini, B. I., Lee, J.-L., Kroeger, N., & Heng, D. Yc. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. BRITISH JOURNAL OF CANCER, 110(8), 1917-1922.

The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium
Schutz, F. Ab., Xie, W., Donskov, F., Sircar, M., McDermott, D. F., & Choueiri, T. K. (2014). The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. EUROPEAN UROLOGY, 65(4), 723-730.

Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., & Choueiri, T. K. (2014). Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. EUROPEAN UROLOGY, 65(3), 577-584.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
Heng, D. Yc., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., & Wood, L. A. (2014). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. ANNALS OF ONCOLOGY, 25(1), 149-154.

Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2013). Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(12), 1471-1479.

Prostate cancer, version 1.2014.
Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., & Ho, M. (2013). Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network , 11(12), 1471-1479.

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
Kroeger, N., Xie, W., Lee, J.-L., Bjarnason, G. A., Knox, J. J., & Heng, D. Yc. (2013). Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. CANCER, 119(16), 2999-3006.

A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer.
Dreicer, R., Garcia, J., Rini, B., Vogelzang, N., Srinivas, S., & Raghavan, D. (2013). A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Investigational new drugs, 31(4), 1044-1050.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
Harshman, L. C., Barbeau, S., McMillian, A., & Srinivas, S. (2013). A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clinical genitourinary cancer, 11(2), 100-106.

Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
Harshman, L. C., Yu, R. J., Allen, G. I., Srinivas, S., Gill, H. S., & Chung, B. I. (2013). Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 31(3), 379-385.

The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients.
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC. Heart failure, 1(1), 72-78.

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., & Hussain, M. (2013). Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. JOURNAL OF CLINICAL ONCOLOGY, 31(4), 412-419.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., & Srinivasan, R. (2013). Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of clinical oncology , 31(2), 181-186.

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Ryan, C. J., Rosenthal, M., Ng, S., Alumkal, J., Picus, J., & Gerritsen, W. R. (2013). Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clinical cancer research , 19(1), 215-224.

mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer
Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., & Talasaz, Aa. H. (2012). mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer. PLOS ONE, 7(11).

Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance
Patel, P., Balise, R., & Srinivas, S. (2012). Variations in Normal Serum Alpha-Fetoprotein (AFP) Levels in Patients with Testicular Cancer on Surveillance. ONKOLOGIE, 35(10), 588-591.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
Harshman, L. C., Xie, W., Bjarnason, G. A., Knox, J. J., MacKenzie, M., & Choueiri, T. K. (2012). Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. LANCET ONCOLOGY, 13(9), 927-935.

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., & Shead, D. A. (2012). Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(9), 1081-1087.

Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease
Dreicer, R., Garcia, J., Hussain, M., Rini, B., Vogelzang, N., & Raghavan, D. (2011). Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. INVESTIGATIONAL NEW DRUGS, 29(6), 1441-1448.

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., & Ross, R. W. (2011). Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer. UROLOGY, 78(3), 626-630.

Toxicities of targeted agents in advanced renal cell carcinoma.
Patel, P., & Srinivas, S. (2011). Toxicities of targeted agents in advanced renal cell carcinoma. Current clinical pharmacology, 6(3), 181-188.

Pyoderma Gangrenosum With the Use of Sunitinib
Nadauld, L. D., Miller, M. B., & Srinivas, S. (2011). Pyoderma Gangrenosum With the Use of Sunitinib. JOURNAL OF CLINICAL ONCOLOGY, 29(10), E266-E267.

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, & Srinivas S. (2011). NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. J Natl Compr Canc Network, 9.

Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients
Harshman, L. C., Bepler, G., Zheng, Z., Higgins, J. P., Allen, G. I., & Srinivas, S. (2010). Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU INTERNATIONAL, 106(11), 1805-1811.

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Pili, R., Rosenthal, M. A., Mainwaring, P. N., van Hazel, G., Srinivas, S., & Clingan, P. (2010). Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. CLINICAL CANCER RESEARCH, 16(10), 2906-2914.

Prostate Cancer
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., & Walsh, P. C. (2010). Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(2), 162-200.

The bevacizumab experience in advanced renal cell carcinoma
Harshman, L. C., & Srinivas, S. (2010). The bevacizumab experience in advanced renal cell carcinoma. ONCOTARGETS AND THERAPY, 3, 179-189.

Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer
Bazan JG, King CR, Brooks JD, & Srinivas S. (2010). Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer. Open Prostate Cancer Journal, 3.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Escudier, B., Roigas, J., Gillessen, S., Harmenberg, U., Srinivas, S., & Vogelzang, N. J. (2009). Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 27(25), 4068-4075.

A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer
Srinivas, S., & Feldman, D. (2009). A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. ANTICANCER RESEARCH, 29(9), 3605-3610.

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib
Harshman, L. C., Srinivas, S., Kamaya, A., & Chung, B. I. (2009). Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. NATURE REVIEWS UROLOGY, 6(6), 338-343.

Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer
Krishnan AV, Srinivas S, & Feldman D. (2009). Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer. Dermato Endocrinolgy, 1.

A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma
Srinivas, S., & Harshman, L. C. (2009). A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma. CHEMOTHERAPY, 55(5), 321-326.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma
Harshman, L. C., Kuo, C. J., Wong, B. Y., Vogelzang, N. J., & Srinivas, S. (2009). Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma. CANCER INVESTIGATION, 27(8), 851-856.

High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience.
Agarwal R, Dvorak CC, Stockerl- Goldstein KE, Johnson L, & Srinivas S. (2009). High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. Bone Marrow Transplant, 43(7).

Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.
Krishnan, A. V., Srinivas, S., & Feldman, D. (2009). Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermato-endocrinology, 1(1), 7-11.

The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer
Harshman, L. C., Li, M., & Srinivas, S. (2008). The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma - Is Not the Answer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(5), 417-423.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613-1618.

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
Jonasch, E., Stadler, W. M., Bukowski, R. M., Hayes, T. G., Varadhachary, A., & Srinivas, S. (2008). Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. CANCER, 113(1), 72-77.

Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer
Harshman, L., & Srinivas, S. (2008). Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. ONKOLOGIE, 31(8-9), 432-433.

Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma
Harshman, L. C., & Srinivas, S. (2007). Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. EXPERT REVIEW OF ANTICANCER THERAPY, 7(12), 1749-1761.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., & McDermott, D. (2007). Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(29), 4536-4541.

Acute pancreatitis associated with sorafenib
Li, M., & Srinivas, S. (2007). Acute pancreatitis associated with sorafenib. SOUTHERN MEDICAL JOURNAL, 100(9), 909-911.

Prostate cancer. Clinical practice guidelines in oncology.
Mohler, J., Babaian, R. J., Bahnson, R. R., Boston, B., D'Amico, A., & Walsh, P. C. (2007). Prostate cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 5(7), 650-683.

Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer
Feldman, D., Krishnan, A., Moreno, J., Swami, S., Peehl, D. M., & Srinivas, S. (2007). Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. NUTRITION REVIEWS, 65(8), S113-S115.

Bone related events in high risk prostate cancer
Srinivas, S., & Colocci, N. (2006). Bone related events in high risk prostate cancer. JOURNAL OF UROLOGY, 176(6), S50-S54.

Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
King, C. R., McNeal, J. E., Gill, H., Brooks, J. D., Srinivas, S., & Presti, J. C. (2006). Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. UROLOGY, 67(6), 1229-1234.

Nonplatinum therapy in advanced bladder cancer
Srinivas, S., & Colocci, N. (2006). Nonplatinum therapy in advanced bladder cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 6(6), 887-894.

Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer
Srinivas, S., Krishnan, A. V., Colocci, N., & Feldman, D. (2006). Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. UROLOGY, 67(5), 1001-1006.

Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy
Liu, I. J., Lai, Y.-H., Espiritu, J. I., Segall, G. M., Srinivas, S., & Terris, M. K. (2006). Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. UROLOGIA INTERNATIONALIS, 77(1), 69-75.

Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Badger, J., Kang, S., Uzieblo, A., & Srinivas, S. (2005). Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. Journal of clinical oncology , 23(28), 7224-7225.

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma
Srinivas, S., & Guardino, A. E. (2005). A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU INTERNATIONAL, 96(4), 536-539.

A nonplatinum combination in metastatic transitional cell carcinoma
Srinivas, S., & Guardino, A. E. (2005). A nonplatinum combination in metastatic transitional cell carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 28(2), 114-118.

Node Positive Bladder Cancer
Srinivas S, & Freiha F. (2005). Node Positive Bladder Cancer. Arab J Urology, 3.

Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis
Morgan, K., Srinivas, S., & Freiha, F. S. (2004). Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. UROLOGY, 64(4).

Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily
Murphy, J. C., Srinivas, S., & Terris, M. K. (2004). Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. JOURNAL OF ANDROLOGY, 25(4), 630-634.

Positron emission tomography in the initial staging of esophageal cancer
Wren, S. M., Stijns, P., & Srinivas, S. (2002). Positron emission tomography in the initial staging of esophageal cancer. ARCHIVES OF SURGERY, 137(9), 1001-1006.

Utility of bone scan post primary therapy in prostate cancer
Srinivas S. (2002). Utility of bone scan post primary therapy in prostate cancer. UroOncology.

Management choices in stage I non-seminomatous Germ Cell Tumor
Srinivas S, & Terris MK. (2001). Management choices in stage I non-seminomatous Germ Cell Tumor. UroOncology.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer
Kiratli, B. J., Srinivas, S., Perkash, I., & Terris, M. K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. UROLOGY, 57(1), 127-132.

High-dose chemotherapy in poor-risk germ-cell tumors
Srinivas, S. (2000). High-dose chemotherapy in poor-risk germ-cell tumors. ONCOLOGY-NEW YORK, 14(10), 1419-1423.

Spontaneous pneumothorax in malignancy: A case report and review of the literature
Srinivas, S., & Varadhachary, G. (2000). Spontaneous pneumothorax in malignancy: A case report and review of the literature. ANNALS OF ONCOLOGY, 11(7), 887-889.

Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer.
Durski, J. M., Srinivas, S., & Segall, G. (2000). Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 3(3), 97-105.

Actinomycin D revisited in testicular cancer. A case report
Srinivas, S., & Freiha, F. S. (1999). Actinomycin D revisited in testicular cancer. A case report. TUMORI, 85(1), 78-79.

Tool support for authoring eligibility criteria for cancer trials
Rubin, D. L., Gennari, J. H., Srinivas, S., Yuen, A., Kaizer, H., & Silva, J. S. (1999). Tool support for authoring eligibility criteria for cancer trials. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 369-373.

Methotrexate tolerance in patients with ileal conduits and continent diversions
Srinivas, S., Mahalati, K., & Freiha, F. S. (1998). Methotrexate tolerance in patients with ileal conduits and continent diversions. CANCER, 82(6), 1134-1136.

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
Small, E. J., Srinivas, S., Egan, B., McMillan, A., & Rearden, T. P. (1996). Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 14(5), 1617-1625.

THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER
Small, E. J., & Srinivas, S. (1995). THE ANTIANDROGEN WITHDRAWAL SYNDROME - EXPERIENCE IN A LARGE COHORT OF UNSELECTED PATIENTS WITH ADVANCED PROSTRATE CANCER. CANCER, 76(8), 1428-1434.

THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993). THE WEIGHT-BASED HEPARIN DOSING NOMOGRAM COMPARED WITH A STANDARD CARE NOMOGRAM - A RANDOMIZED CONTROLLED TRIAL. ANNALS OF INTERNAL MEDICINE, 119(9), 874-881.

INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES
Reilly, B. M., Raschke, R., Srinivas, S., & Nieman, T. (1993). INTRAVENOUS HEPARIN DOSING - PATTERNS AND VARIATIONS IN INTERNISTS PRACTICES. JOURNAL OF GENERAL INTERNAL MEDICINE, 8(10), 536-542.